University of Tübingen and Boehringer Ingelheim launch scholarship program for AI and data science

University of Tübingen and Boehringer Ingelheim launch scholarship program for AI and data science

The University of Tübingen, a leading member of Cyber ​​Valley, Europe's largest artificial intelligence (AI) research consortium, and Boehringer Ingelheim are launching an AI and data science scholarship program for top talent from around the world. Three to five scholarships are awarded each year for a period of up to three years, with the program aiming to have nine to fifteen scholarship recipients after five years.

Jan Nygaard Jensen, Global Head of Computational Biology and Digital Sciences at Boehringer Ingelheim. Image source: Boehringer Ingelheim

The partners define cutting-edge research topics at the intersection of health and AI applications, which are selected by a joint steering committee. The first scholarships have been published here and interested postdoctoral researchers are cordially invited to submit their applications.

The partnership is based on the shared vision of Boehringer Ingelheim and the University of Tübingen to harness the power of AI and data science to improve human and animal health. The goal is to transform patients' lives by discovering new medical breakthroughs, accelerating timelines, improving scientific and clinical success, and further increasing patient centricity. The areas of application extend across the entire biopharmaceutical value chain, from research and development to production and supply chain management to marketing and sales.

The partnership with the University of Tübingen will advance our AI and data science research and give us the opportunity to develop and recruit the next generation of AI and data scientists. These talents will be critical to achieving our goal of accelerating the development of novel treatments and transforming the lives of millions of people and animals.”

Jan Nygaard Jensen, Global Head of Computational Biology and Digital Sciences, Boehringer Ingelheim

"Only by harnessing the potential of new digital technologies can we achieve our goal of delivering the future of healthcare to people around the world. That's why digital innovation at Boehringer Ingelheim extends across all areas as part of a unified strategy to maximize these opportunities. That's who we are." We are excited to work with the fellows to expand our leadership in developing next-generation AI and data science solutions,” added Brigitte Fuhr, Head of Central Data Science at Boehringer Ingelheim.

This collaboration with a research-focused biopharmaceutical company such as Boehringer-Ingelheim is a partnership of mutual interest and could pave the way for further initiatives. Here the university creates another interface between basic research and practical application. It also raises its profile in a research area of ​​increasing importance: the use of AI in medicine and the life sciences.”

Professor Dr. Peter Grathwohl, Vice President for Research and Innovation, University of Tübingen

“The combination of AI with relevant health and pharmaceutical data has great potential to noticeably improve the well-being of many people,” says Nico Pfeifer, Professor of Medical Informatics Methods at the University of Tübingen and project leader. “Methodology research is able to identify problems in healthcare that require new AI approaches and develop tailored solutions for them.”

The fellows will conduct their research on site at the University of Tübingen. You will benefit from the university's extensive expertise, rapid growth in AI and data science, and renowned medical research. In addition, they have the opportunity to work closely with Boehringer Ingelheim scientists, subject matter experts and executives worldwide and locally. In addition, it is planned that the scholarship holders will be invited to visits to company locations, networking events and annual symposia.

The University of Tübingen is committed to the transfer of innovations and research results into application and to continuous exchange with business and society. In the field of AI, it is a founding member of the Cyber ​​Valley research network and conducts applied basic research in a variety of collaborations. The focus is on applications for science itself – for example in the Cluster of Excellence “Machine Learning: New Perspectives for Science” – life sciences and medicine, but also ethical aspects.

Boehringer Ingelheim's digital strategy aims to build a leading data science ecosystem by collaborating with world-class academic research institutions in the field, supporting and developing future talent, and collaborating with data initiatives around the world to build a comprehensive global database of genomic and patient data. The company cooperates with innovative digital startups along the entire value chain and invests in early digital entrepreneurs through the company's own venture fund BIVF.

With the newly established collaboration with the University of Tübingen, Boehringer Ingelheim continues to promote AI and data science partnerships at several innovation locations in Europe, the USA and Asia. Last year, a similar grant program was established with Yale University along with Boehringer Ingelheim's Ridgefield research and development site.

Source:

Boehringer Ingelheim

.